MetaCap

IRulya Therapeutics (IRLA) vs Tevogen (TVGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IRulya Therapeutics is the larger company by market cap ($432.4 million vs $405.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRLA+17.16%TVGN-14.12%
+21%-1%-24%
Aug 14, 20261 yearNov 20, 2026
IRLA+17.16%TVGN-14.12%
+19%-1%-20%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRLA versus TVGN key metrics
MetricIRLATVGN
Share price$39.88$5.90
Market cap$432.36M$405.20M
1-day change-0.15%-6.35%
YTD return—-64.35%
1-year return—-73.84%
EPS (TTM)$-162.79$-7.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-83.98M$-26.28M
52-week high$910.00$24.90
52-week low$15.10$3.64
Distance from 52-week high-95.62%-76.31%
Analyst consensusstrong_buy—
Avg. price target upside+90.90%—
Average volume63.03K7.94K
Shares outstanding10.84M68.68M
Employees3818
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About IRulya Therapeutics

IRLA stock →

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees

About Tevogen

TVGN stock →

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

IRLA vs TVGN FAQ

Which is bigger, IRulya Therapeutics or Tevogen?

IRulya Therapeutics (IRLA) is larger, with a market capitalization of $432.36M compared with $405.20M for Tevogen (TVGN).

Are IRulya Therapeutics and Tevogen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons